Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy - Wikidata - awgldk - TriplyDB

Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy

Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy

http://www.wikidata.org/entity/Q36793779

about

Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Respons Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial.Standardizing of Pathology in Patients Receiving Neoadjuvant Chemotherapy.Neoadjuvant chemotherapy in breast cancers.Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery.An audit of residual cancer burden reproducibility in a UK context.Innovations in Clinical Trial Design in the Era of Molecular Profiling.Automatic cellularity assessment from post-treated breast surgical specimens.Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.The ever-evolving role of pathologists in the management of breast cancer with neoadjuvant treatment: recommendations based on the Spanish clinical experience.Inter-observer agreement among pathologists in grading the pathological response to neoadjuvant chemotherapy in breast cancer.

P2860

Q27304609-52BAB5E2-A171-4E56-9AD9-50E22DCFABE7 Q30253017-30BE188B-98D7-4FAF-9F7C-0AE9854CD714 Q38430990-CD701593-1C29-4C63-993C-1A5EB7D0CE04 Q38886900-E9B7FFCA-D006-48E7-B32B-3866507351A0 Q39019234-2E4D245C-FD1A-440B-8901-CD7F4BB7445F Q39109484-EE41D6F5-E890-4E63-B1B2-546BECE22F07 Q39299810-CCACEB65-BB29-4B17-89F6-48871CF813E0 Q39519094-59A48822-AC65-482D-978C-9C7E59844516 Q45059047-2574BEB0-BCCA-4526-991B-8020D0EA748D Q45945233-E0541BAB-FD6A-45DD-A569-3FFE47F843C3 Q47273306-7E4217DD-5296-4748-A921-0C78FF76EF3A Q48262301-5680E5A2-5CCB-4F89-8F3A-8324C5C3F332 Q50198110-57A1ED71-8CC7-4FEB-A589-DA97B05C0AE5

P2860

Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy

http://www.wikidata.org/entity/Q36793779

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Reproducibility of residual ca ...... after neoadjuvant chemotherapy

@ast

Reproducibility of residual ca ...... after neoadjuvant chemotherapy

@en

type

label

Reproducibility of residual ca ...... after neoadjuvant chemotherapy

@ast

Reproducibility of residual ca ...... after neoadjuvant chemotherapy

@en

prefLabel

Reproducibility of residual ca ...... after neoadjuvant chemotherapy

@ast

Reproducibility of residual ca ...... after neoadjuvant chemotherapy

@en

P1433

Q36793779-A26ACBB8-D0C4-43E4-A8AE-5B898FB58527

P1476

Q36793779-F30E3C12-BE6B-439A-B132-A83D5DFE6197

P2093

Q36793779-135A159F-CFA3-4105-84CC-EEE4BD43408E

Q36793779-73F16E28-8775-4832-9609-E8C38B3F47B7

Q36793779-9E8E620B-FBD6-4060-BE6F-7282636BFF68

Q36793779-A079C11A-1798-4334-B248-CAB2AF373207

Q36793779-AE08E374-ED77-445D-AF8B-C75C40B28A12

Q36793779-CCF82AAF-E826-495C-93A1-68AA00703F2B

Q36793779-D1B43764-DF2C-439C-BD0A-D0E07615217B

P2860

Q36793779-154A6822-BC07-4FB6-A0DB-4E1A03E2AB63

Q36793779-79864A03-6A06-4055-B5B2-1EA7BA5CE4AC

Q36793779-7CAC9BDC-81CA-4033-80D3-27A8145CA8EA

Q36793779-95FA1AE4-2031-4D1D-8A59-0B603ABE46D4

Q36793779-A4CD4EC0-C688-46A1-AA87-1B19A76F862E

Q36793779-AC01E68B-A4BF-4679-8302-A1062CCB9420

Q36793779-D78E352F-2A94-43B7-92E0-42CDC3C133BA

Q36793779-E4E99C01-7C6E-45C9-A21A-BB86ACAA5479

Q36793779-EF3B7177-BC9A-4A76-80C6-229FF6FA8596

P2888

Q36793779-BB55AEB2-CDB4-4953-84C2-75215C7C65E5

P304

Q36793779-C0D1CA2C-80E2-43D5-A3E7-ED580193B35F

P31

Q36793779-6013B594-7C99-47ED-806A-DA47C9776C05

P356

Q36793779-4A6BCA41-CB01-47F7-B178-7874ACFF468B

P433

Q36793779-F88DA7ED-9458-4E94-BB98-0C490539755C

P478

Q36793779-CA9FD10A-CD01-4F35-8C97-411A55F78747

P50

Q36793779-184126C2-779A-480D-8BBE-84B6103E0E79

P577

Q36793779-53DA38DB-5032-43E3-B27E-10BCFCF1112F

P5875

Q36793779-02C511F1-4279-4A0B-BDCC-EE7A4339BAB5

P6179

Q36793779-56D3258D-FF2E-4BE8-A5BD-EF5C73A8A68F

P698

Q36793779-0C7B3402-90B5-4A1F-90B7-E34F0E3B6BE8

P921

Q36793779-98963A8B-1537-4178-AAF3-6DC8AABACFB8

Q36793779-9C2C9182-4215-41B6-A01C-FC9040D2EDD7

P932

Q36793779-B8D9BE59-E04A-4E7A-AA7C-5606EA0B5E04

P356

MODPATHOL.2015.53

P1433

Modern Pathology

P1476

Reproducibility of residual ca ...... after neoadjuvant chemotherapy

@en

P2093

Bruno Sinn

http://www.w3.org/2001/XMLSchema#string

Constance Albarracin

http://www.w3.org/2001/XMLSchema#string

Erinn Downs-Kelly

http://www.w3.org/2001/XMLSchema#string

Florentia Peintinger

http://www.w3.org/2001/XMLSchema#string

Jerzy Morkowski

http://www.w3.org/2001/XMLSchema#string

Rebekah Gould

http://www.w3.org/2001/XMLSchema#string

W Fraser Symmans

http://www.w3.org/2001/XMLSchema#string

P2860

A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial.

Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.

An international Ki67 reproducibility study.

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

Assessment of CAD-generated tumor volumes measured using MRI in breast cancers before and after neoadjuvant chemotherapy.

Overall concordance correlation coefficient for evaluating agreement among multiple observers.

P2888

modpathol.2015.53

P304

913-920

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MODPATHOL.2015.53

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Christos Hatzis

P577

2015-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

275663296

http://www.w3.org/2001/XMLSchema#string

P6179

1002438737

http://www.w3.org/2001/XMLSchema#string

P698

25932963

http://www.w3.org/2001/XMLSchema#string

P921

reproducibility

P932

4830087

http://www.w3.org/2001/XMLSchema#string